H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX)

September 9, 2025 6:50 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $4.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login